Announced
Synopsis
AGC, a global contract development and manufacturing organization, offered to acquire Molmed, a biotechnology company, for $267m. AGC offered $0.577 per Molmed share, the equivalent of a premium of 110.3% compared to the stock’s closing price on March 16.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.